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BACKGROUND
CF is a life limiting, autosomal recessive condition. It affects 1 in 2000-3000
newborns in the European Union and 1 in 3500 newborns within the United
States of America¹. Currently, within the UK around 10,000 people suffer from
CF².
CF is a multisystem disorder which requires long term, specialist
multidisciplinary team (MDT) care in order to manage the many treatment
decisions and aspects of CF disease effectively. Treatment varies from patient to
patient according to the nature and severity of their symptoms and includes but
is not limited to airway clearance, pancreatic enzyme replacement, dietary
supplementation, antibiotics and nebulisers.
There are many uncertainties regarding Cystic Fibrosis (CF) treatment. Well-
designed clinical trials should focus on questions which are important to patients
and clinicians. Recently, the first James Lind Alliance (JLA) Priority Setting
Partnership (PSP) in CF was completed3, bringing clinicians, patients and carers
together to identify the Top 10 research priorities. Now that we know which
treatment uncertainties are most important to the CF community, we want to
examine how these priorities are reflected in the current clinical trial landscape.
We aim to do this by carrying out a systematic review of the clinical trials
registries and mapping the results to the James Lind Top ten.
REVIEW QUESTION
The review aims to identify current clinical trials on cystic fibrosis treatments and
to find out how well these trials reflect the James Lind Alliance top ten priorities
for research.
SEARCHES
Databases: PubMed; Australia and New Zealand Clinical Trials Register; EU
Clinical Trials register; Clinicaltrials.gov; ISRCTN
Dates searched: 1st January 2016 – 9th November 2017
Language restrictions: only those trials published in English
The terms “cystic fibrosis” and where possible “interventional” were used.
Non registry studies were found by contacting relevant members of the Cystic
Fibrosis Foundation regarding the Success with Therapies Research Consortium
(STRC), CF health hub.
Search strategies are in Appendix 1
CONDITION BEING STUDIED
Treatment interventions for adults and children with cystic fibrosis.
PARTICIPANTS/POPULATION
Participants diagnosed with CF (through genetic testing or sweat testing) and of
any age. Studies including other conditions but where CF patients are analysed
as a specific subgroup were included if they met the rest of the inclusion criteria.
INTERVENTION(S)
Studies of treatment interventions in CF will be included. Studies involving trials
of combinations of interventions, timings and duration of intervention and
stopping interventions will also be included.
Studies covering diagnosis, newborn screening or those concerning diagnostic
test accuracy will be excluded as well as those concerning policy, evaluation of
the training of physicians or organisation of care.
The interventions we include will likely fall into these categories: drugs
interventions (antibiotics and CFTR modulators), behavioural interventions
(supportive care etc), dietary interventions (vitamin D, fibre etc), device or web
based interventions (trackers, smartphone apps or virtual reality etc) and other
interventions such as home monitoring and exercise for example.
COMPARATOR(S)/CONTROL
The comparator will be either be a placebo, usual treatment or no treatment.
TYPES OF STUDY TO BE INCLUDED
The study type we are looking for is interventional clinical trials of treatments for
CF. We will include completed and ongoing trials.
CONTEXT
Setting includes inpatient and outpatient treatments in primary and secondary
care and includes any trial that confers patient benefit.
PRIMARY OUTCOME(S)
The primary outcome is any clinically meaningful outcome which reflects patient
benefit. We expect the outcomes to fall into the following categories but this list
is not exclusive:
 Lung Function (e.g. FEV1,FVC, Lung clearance index etc)
 Health-related quality of life validated measures (e.g. Cystic Fibrosis
Questionnaire (CFQ) 26)
 Respiratory symptom outcomes (e.g. Respiratory and Systemic Symptoms
Questionnaire RSSQ)
 Hospitalisation (e.g. number of nights inpatient)
 School/Work attendance (e.g. number of days missed)
 Nutrition & Growth (e.g. weight gain, height, fat)
 Radiological (e.g. bone mineral density)
 Sputum properties
 Pulmonary exacerbations (measured by frequency of exacerbation or time to
next exacerbation etc)
 Antibiotic use (e.g. number of courses, combinations, delivery method)
 Adverse effects (toxicity & allergy, microbiology, complication of delivery)
 Exercise tolerance
 Sweat chloride as a measure of CFTR function
 Mucus clearance
 Nasal symptom scores
 Bowel symptoms (e.g. stool frequency, abdominal pain etc)
 Treatment burden
 Treatment adherence
 Cost
SECONDARY OUTCOME(S)
There are no secondary outcomes
DATA EXTRACTION
Electronic search results will be collated into an Excel document. Studies found
through other searches will be assembled into a separate Excel document.
Where possible, data on study title, recruitment, intervention, outcome
measures, sponsor/collaborators/funding and study type will be recorded in the
Excel Document.
For all studies, duplicates will be checked for manually and excluded.
The title/abstract of each study will be scanned by one reviewer and trials that
are not interventional will be excluded. A second reviewer will check those
records where there is uncertainty.
Studies which are deemed to fulfil the inclusion criteria from the title and
abstract will be retrieved in full and scanned again for inclusion. Trials excluded
at this stage will be listed with the reason for exclusion.
Data will be collected on the trial characteristics, the sponsor of the trial and the
funding source.
STRATEGY FOR DATA SYNTHESIS
The primary aim of the review is to match the identified clinical trials with the
top ten priorities for research in CF which were the result of a James Lind
Alliance Priority Setting Partnership.
All available information on the trials will be reviewed in order to extract the
main aims of the trial and to make a decision on the most accurate match of
each study to the Top 10 research priorities. Matching will be recorded in Excel.
A second reviewer will check the matching decisions (NR) to ensure matching
results are as accurate as possible. Any trials with matches made to the Top 10
priorities deemed by the first reviewer to be uncertain and needing a second
opinion will be flagged. A final decision will be made by discussion.
ANALYSIS OF SUBGROUPS OR SUBSETS
Matching of trials to the James Lind Alliance top ten will be done for each priority
in turn.
DISSEMINATION PLANS
We intend to publish the results in a peer reviewed journal and present at the
European CF Society meeting.
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APPENDIX 1
Search strategies used in the systematic review
ClinicalTrials.gov
Condition or disease: 'cystic fibrosis', Study Type: 'Interventional Studies', First
posted: '01/01/2016' to '09/11/2017'
ISRCTN
Condition: 'cystic fibrosis', Date applied '01/01/2016' to '09/11/2017' and
Overall trial start date '01/01/2016' to '09/11/2017'
EU CLINICAL TRIALS REGISTER
Search term 'cystic fibrosis', Date range '2016/01/01' to '2017/11/09'
Pubmed
'cystic fibrosis' in title/abstract, Date- Publication '2016/01/01' to '2017/11/09'
Article types: 'Clinical trials'
(cystic fibrosis[Title/Abstract]) AND ("2016/01/01"[Date - Publication] :
"2017/11/09"[Date - Publication])
ANZCTR
Search term 'cystic fibrosis', Study type: 'Interventional', Trial start date
'01/01/2016' to '09/11/2017' and registration date '01/01/2016' to
'09/11/2017'
